DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N

该项目的主要目标是支持候选产品的高级开发，这些产品由疫苗成分和技术成分组成（干制剂技术），以增加稳定性并最大限度地减少冷链或防腐剂要求，用于故意释放或应对自然发生的由NIAID A、B类引起的传染病爆发后的事后环境，C优先病原体

The primary objective of this project is to support the advanced development of candidate products which consist of a vaccine component in combination with a technology component (a dry formulation technology) to increase stability and minimize cold chain or preservative requirements for use in post-event settings following the intentional release of or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B, and C Priority Pathogens.